A phase of I trial of 4'-epi-Adriamycin.

P. K. Schauer, R. E. Wittes, Richard J. Gralla, E. S. Casper, C. W. Young

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

4'-epi-adriamycin was administered intravenously on an every-3-week schedule to 34 patients with advanced malignant tumors. Patients were treated at five dosage levels, ranging from 40 mg/m2 to 100 mg/m2. Hematologic toxicity was dose limiting. No cardiac, renal, or hepatic toxicity was observed; there were no drug-related deaths. Partial alopecia developed in all patients receiving a cumulative dose of 200 mg/m2; mild nausea and vomiting occurred in 13 patients. Although major therapeutic responses were not seen in this phase I trial, 2 of 15 patients with objectively measurable disease showed minor responses; 7 patients had stabilization of previously progressing cancer for 3 to 5+ months. A dose of 85 mg/m2 of epi-Adriamycin every 3 weeks seems an appropriate initial dose for phase II studies in patients having a performance status of 70 or higher. A starting dose of 70 mg/m2 is recommended for patients having a lower performance status.

Original languageEnglish (US)
Pages (from-to)433-437
Number of pages5
JournalCancer Clinical Trials
Volume4
Issue number4
StatePublished - Dec 1981
Externally publishedYes

Fingerprint

Epirubicin
Alopecia
Doxorubicin
Nausea
Vomiting
Neoplasms
Appointments and Schedules
Kidney
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schauer, P. K., Wittes, R. E., Gralla, R. J., Casper, E. S., & Young, C. W. (1981). A phase of I trial of 4'-epi-Adriamycin. Cancer Clinical Trials, 4(4), 433-437.

A phase of I trial of 4'-epi-Adriamycin. / Schauer, P. K.; Wittes, R. E.; Gralla, Richard J.; Casper, E. S.; Young, C. W.

In: Cancer Clinical Trials, Vol. 4, No. 4, 12.1981, p. 433-437.

Research output: Contribution to journalArticle

Schauer, PK, Wittes, RE, Gralla, RJ, Casper, ES & Young, CW 1981, 'A phase of I trial of 4'-epi-Adriamycin.', Cancer Clinical Trials, vol. 4, no. 4, pp. 433-437.
Schauer PK, Wittes RE, Gralla RJ, Casper ES, Young CW. A phase of I trial of 4'-epi-Adriamycin. Cancer Clinical Trials. 1981 Dec;4(4):433-437.
Schauer, P. K. ; Wittes, R. E. ; Gralla, Richard J. ; Casper, E. S. ; Young, C. W. / A phase of I trial of 4'-epi-Adriamycin. In: Cancer Clinical Trials. 1981 ; Vol. 4, No. 4. pp. 433-437.
@article{20b861bdee104a859f8b450c8c0c8e89,
title = "A phase of I trial of 4'-epi-Adriamycin.",
abstract = "4'-epi-adriamycin was administered intravenously on an every-3-week schedule to 34 patients with advanced malignant tumors. Patients were treated at five dosage levels, ranging from 40 mg/m2 to 100 mg/m2. Hematologic toxicity was dose limiting. No cardiac, renal, or hepatic toxicity was observed; there were no drug-related deaths. Partial alopecia developed in all patients receiving a cumulative dose of 200 mg/m2; mild nausea and vomiting occurred in 13 patients. Although major therapeutic responses were not seen in this phase I trial, 2 of 15 patients with objectively measurable disease showed minor responses; 7 patients had stabilization of previously progressing cancer for 3 to 5+ months. A dose of 85 mg/m2 of epi-Adriamycin every 3 weeks seems an appropriate initial dose for phase II studies in patients having a performance status of 70 or higher. A starting dose of 70 mg/m2 is recommended for patients having a lower performance status.",
author = "Schauer, {P. K.} and Wittes, {R. E.} and Gralla, {Richard J.} and Casper, {E. S.} and Young, {C. W.}",
year = "1981",
month = "12",
language = "English (US)",
volume = "4",
pages = "433--437",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A phase of I trial of 4'-epi-Adriamycin.

AU - Schauer, P. K.

AU - Wittes, R. E.

AU - Gralla, Richard J.

AU - Casper, E. S.

AU - Young, C. W.

PY - 1981/12

Y1 - 1981/12

N2 - 4'-epi-adriamycin was administered intravenously on an every-3-week schedule to 34 patients with advanced malignant tumors. Patients were treated at five dosage levels, ranging from 40 mg/m2 to 100 mg/m2. Hematologic toxicity was dose limiting. No cardiac, renal, or hepatic toxicity was observed; there were no drug-related deaths. Partial alopecia developed in all patients receiving a cumulative dose of 200 mg/m2; mild nausea and vomiting occurred in 13 patients. Although major therapeutic responses were not seen in this phase I trial, 2 of 15 patients with objectively measurable disease showed minor responses; 7 patients had stabilization of previously progressing cancer for 3 to 5+ months. A dose of 85 mg/m2 of epi-Adriamycin every 3 weeks seems an appropriate initial dose for phase II studies in patients having a performance status of 70 or higher. A starting dose of 70 mg/m2 is recommended for patients having a lower performance status.

AB - 4'-epi-adriamycin was administered intravenously on an every-3-week schedule to 34 patients with advanced malignant tumors. Patients were treated at five dosage levels, ranging from 40 mg/m2 to 100 mg/m2. Hematologic toxicity was dose limiting. No cardiac, renal, or hepatic toxicity was observed; there were no drug-related deaths. Partial alopecia developed in all patients receiving a cumulative dose of 200 mg/m2; mild nausea and vomiting occurred in 13 patients. Although major therapeutic responses were not seen in this phase I trial, 2 of 15 patients with objectively measurable disease showed minor responses; 7 patients had stabilization of previously progressing cancer for 3 to 5+ months. A dose of 85 mg/m2 of epi-Adriamycin every 3 weeks seems an appropriate initial dose for phase II studies in patients having a performance status of 70 or higher. A starting dose of 70 mg/m2 is recommended for patients having a lower performance status.

UR - http://www.scopus.com/inward/record.url?scp=0019760377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019760377&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 433

EP - 437

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -